Abstract

BackgroundThe overall goal of this study was to demonstrate potential chemopreventive effects of ferulic acid (FA), an antioxidant, combined with aspirin (ASP), a commonly used anti-inflammatory drug for pancreatic cancer chemoprevention, using a novel chitosan-coated solid lipid nanoparticles (c-SLN) drug delivery system encapsulating FA and ASP.ResultsOur formulation optimization results showed that c-SLNs of FA and ASP exhibited appropriate initial particle sizes in range of 183 ± 46 and 229 ± 67 nm, encapsulation efficiency of 80 and 78 %, and zeta potential of 39.1 and 50.3 mV, respectively. In vitro studies were conducted to measure growth inhibition and degree of apoptotic cell death induced by either FA or ASP alone or in combination. Cell viability studies demonstrated combinations of low doses of free FA (200 µM) and ASP (1 mM) significantly reduced cell viability by 45 and 60 % in human pancreatic cancer cells MIA PaCa-2 and Panc-1, respectively. However, when encapsulated within c-SLNs, a 5- and 40-fold decreases in dose of FA (40 µM) and ASP (25 µM) was observed which was significant. Furthermore, increased apoptosis of 35 and 31 % was observed in MIA PaCa-2 and Panc-1 cells, respectively. In vivo studies using oral administration of combinations of 75 and 25 mg/kg of FA and ASP c-SLNs to MIA PaCa-2 pancreatic tumor xenograft mice model suppressed the growth of the tumor by 45 % compared to control, although this was not statistically significant. In addition, the immunohistochemical analysis of tumor tissue showed significant decrease in expression of proliferation proteins PCNA and MKI67, and also increased expression of apoptotic proteins p-RB, p21, and p-ERK1/2 indicating the pro-apoptotic role of the regimen.ConclusionCombination of FA and ASP delivered via a novel nanotechnology-based c-SLN formulation demonstrates potential for pancreatic cancer chemoprevention and could be a promising area for future studies.

Highlights

  • The overall goal of this study was to demonstrate potential chemopreventive effects of ferulic acid (FA), an antioxidant, combined with aspirin (ASP), a commonly used anti-inflammatory drug for pancreatic cancer chemoprevention, using a novel chitosan-coated solid lipid nanoparticles (c-SLN) drug delivery system encapsulating FA and ASP

  • Physical characterization of FA and ASP encapsulated chitosan solid lipid nanoparticles (c‐SLNs) Based on the methodology described earlier [3, 9], c-SLNs of FA and ASP exhibited initial particle sizes in the nanometer range of 183 ± 46 and 229 ± 67, respectively

  • We evaluated the expression of phosphorylated retinoblastoma (p-RB) protein, phospho-extracellular signal-regulated kinases (ERK1/2) and p21 protein expression using IHC

Read more

Summary

Introduction

The overall goal of this study was to demonstrate potential chemopreventive effects of ferulic acid (FA), an antioxidant, combined with aspirin (ASP), a commonly used anti-inflammatory drug for pancreatic cancer chemoprevention, using a novel chitosan-coated solid lipid nanoparticles (c-SLN) drug delivery system encapsulating FA and ASP. Current treatment modalities are largely ineffective, bringing to the forefront the development of alternative strategies to tackle this disease [2]. A viable strategy could be the use of chemopreventive agents to suppress, delay or even reverse the onset of the disease [3,4,5]. Our group has been interested in the use of novel chemopreventive agents and their combinations for pancreatic cancer prevention. We have demonstrated the importance of delivering these agents using novel nanotechnology-based drug delivery systems

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call